ⓘ Afucosylated monoclonal antibodies

                                     

ⓘ Afucosylated monoclonal antibodies

Afucosylated monoclonal antibodies are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units. When antibodies are afucosylated the effect is to increase antibody-dependent cellular cytotoxicity.

                                     
  • Complement - dependent cytotoxicity Afucosylated monoclonal antibodies Hashimoto, G. Wright, P. F. Karzon, D. T. 1983 - 11 - 01 Antibody - dependent cell - mediated
  • Pharmaceuticals business The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out
  • reduce antigen - dependent cellular cytotoxicity. Therefore, afucosylated monoclonal antibodies have been designed to recruit the immune system to cancers
  • Mogamulizumab trade name Poteligeo is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 CCR4 The US FDA approved it
  • Swiss Federal Institute of Technology in Zurich to develop afucosylated monoclonal antibodies GA101 was one of its lead products when it was acquired by
  • CHO cell line in which FUT8 has been knocked out to make afucosylated monoclonal antibodies GRCh38: Ensembl release 89: ENSG00000033170 - Ensembl, May
  • GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline GSK for autoimmune diseases. The antibody targets the T cell activation marker
  • for depletion of these cells in eosinophilic disorders by using afucosylated antibodies EGF module - containing mucin - like hormone receptor GRCh38: Ensembl